FSD Pharma Inc
Change company Symbol lookup
Select an option...
HUGE FSD Pharma Inc
DDOG Datadog Inc
CLX Clorox Co
ATTO Atento SA
TOWN TowneBank
CHWY Chewy Inc
O Realty Income Corp
HOOK HOOKIPA Pharma Inc
AI C3.ai Inc
QSG QuantaSing Group Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada

FSD Pharma Inc. is a Canada-based biotechnology company. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its compound, ultra-micronized palmitoyl ethylamine (PEA). The Company, through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. The Company’s wholly owned subsidiaries include Prismic Pharmaceuticals Inc. and FV Pharma Inc.

Postmarket

Last Trade: Delayed
$1.13

Change Since Close Change Since Close Postmarket extended hours change is based on the last price at the end of the regular hours period. Premarket extended hours change is based on the day's regular session close.: -0.03 (-2.59%)

Bid: --

Ask: --

B/A Size: --

Market Hours

Closing Price: $1.16

Day's Change: 0.09 (8.41%)

Bid close: --

Ask close: --

B/A Size: --

Day's High: 1.20

Day's Low: 1.06

Volume (Heavy Day) Volume: 123,010 10-day average volume: 71,801: 123,010

May 25, 2023
7:30 am ET	FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
May 16, 2023
6:00 am ET	InvestmentPitch Media Video Discusses FSD Pharma's Cost Award of $2.81 Million from Dr. Raza Bokhari in an Arbitration Settlement(Globe Newswire)
May 12, 2023
5:00 pm ET	FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
May 11, 2023
7:30 am ET	FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
May 10, 2023
7:30 am ET	FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
May 09, 2023
7:16 am ET	Sidoti's Micro-Cap Virtual May Conference NEW YORK, NY / ACCESSWIRE / May 9, 2023 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject...(Accesswire)
May 08, 2023
8:50 am ET	FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
April 18, 2023
8:45 am ET	North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry FinancialNewsMedia.com News Commentary Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any symptoms of alcohol consumption or drug abuse. These initiatives will most likely...(PR Newswire)
April 17, 2023
9:00 am ET	FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
April 12, 2023
8:30 am ET	FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
March 31, 2023
8:00 pm ET	FSD Pharma Announces Filing of Year-End 2022 Results FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
March 30, 2023
8:30 am ET	FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
March 22, 2023
8:30 am ET	FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)
March 14, 2023
8:30 am ET	FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Postmarket

Change Since Close

Market Hours